Sanofi India Ltd

Sanofi India Ltd has announced that its Board of Directors will convene on August 4, 2026. The primary agenda item for this meeting is to consider and approve the Unaudited Financial Results for the quarter and half-year ended June 30, 2026. Additionally, the company confirmed that the trading window, which was closed from July 1, 2026, in anticipation of these results, will reopen on August 7, 2026. This announcement adheres to SEBI's listing regulations.

Sanofi India Ltd has received a favorable order from the Income Tax Appellate Tribunal - 49, Mumbai, for Assessment Year 2019-20. The tribunal accepted the company's submissions, dropping proceedings initiated under Section 201 of the Income-tax Act, 1961, and deleting a demand of ₹72,71,510. The company was treated as an 'assessee in default' for non-deduction of taxes on year-end provisions. The tribunal ruled that once disallowance is made in tax computation, the company cannot be deemed an 'assessee in default' for the same amount. This ruling has no material impact on Sanofi India's financial or operational activities.

Sanofi India Ltd has announced the closure of its trading window for designated persons. This closure is in accordance with the company's Code of Conduct for Insider Trading and is set to facilitate the declaration of Unaudited Financial Results for the quarter and half-year ending June 30, 2026. The trading window will be shut from July 1, 2026, and will reopen 48 hours after the official announcement of the financial results to the stock exchanges. This measure is standard practice to prevent potential insider trading ahead of significant financial disclosures.

Sanofi India Ltd has disclosed that the Deputy Commissioner, State GST, Ahmedabad, Gujarat, rejected its refund application of INR 11,62,853 for the period 2014-15 to July 2017. The rejection was based on the grounds that the refund claim, arising from a debit to the Electronic Credit Ledger for a mandatory pre-deposit under the Central Excise Act, 1944, was not considered 'tax' eligible for refund under the CGST Act, 2017. The authority also stated that the matter falls under Central GST, not State GST, making the application non-maintainable. Sanofi India plans to file appeals and states there is no material financial or operational impact.

Sanofi India Ltd has received a favorable order from the Superintendent, CGST & C. Ex., Mumbai East Commissionerate, dropping a tax demand of INR 10,56,954 along with applicable interest and penalty. The demand was raised on account of generation of duplicate e-way bills for FY 2018-19. The company's submissions were accepted, and the tax demand has been fully dropped. This outcome has no material impact on the company's financial or operational activities.

Sanofi India Ltd has announced the appointment of Mr. Debajit Roy as the Sales & Customer Engagement Head for its Diabetes division. This appointment, effective from June 8, 2026, designates Mr. Roy as Senior Management Personnel. He brings over 20 years of experience in driving growth across various therapeutic areas, including a recent role as Vice President at Gracewell Specialty and Gracemax, Glenmark Pharmaceuticals. The company has complied with SEBI regulations for this disclosure.

Sanofi India Ltd. announced that the Asst. State Tax Officer, Thripunithura, Kerala, has issued an acceptance order for FY 2020-21. The order accepts submissions made by the company and drops proceedings initiated for verification of tax amounting to ₹59,77,141. The proceedings were related to discrepancies in e-way bills and input tax credit. The company stated that the order has no material impact on its financial, operational, or other activities.

Sanofi India Limited (SIL) has appointed Mr. Rahul Bhatnagar as the Chairman of its Board of Directors, effective April 30, 2026. Mr. Bhatnagar, who joined SIL's Board in 2020, has actively contributed to multiple committees including Audit, Nomination and Remuneration, Corporate Social Responsibility, and Risk Management. He brings extensive expertise in finance, strategy, and governance from leadership positions at global and Indian organizations like Nestlé, PepsiCo, and the Bharti Group. He currently serves as an Independent Director on the Boards of Whirlpool India Limited, Rossell India Limited, TBO TEK Limited & Tasty Bite Eatables Limited. Mr. Bhatnagar succeeds Mr. Aditya Narayan, who completed a decade-long tenure. The Board also acknowledged the conclusion of Mrs. Usha Thorat's tenure. The company anticipates his strategic vision will drive continued growth and excellence.

Sanofi India Ltd's Board of Directors, at its meeting on April 28, 2026, approved the Unaudited Financial Results for the quarter ended March 31, 2026. Additionally, the Board noted the completion of tenure for Independent Directors Mr. Aditya Narayan and Mrs. Usha Thorat, effective April 29, 2026. Mr. Rahul Bhatnagar has been appointed as the new Chairman of the Board, effective April 30, 2026. The company also announced the reconstitution of its Audit Committee, Nomination and Remuneration Committee, Stakeholders Relationship Committee, Risk Management Committee, and Corporate Social Responsibility Committee, effective April 30, 2026.

Sanofi India Ltd's Board of Directors, at its meeting on April 28, 2026, approved the Unaudited Financial Results for the quarter ended March 31, 2026. Additionally, the tenure of Independent Directors Mr. Aditya Narayan and Mrs. Usha Thorat concluded on April 29, 2026. Mr. Rahul Bhatnagar, an Independent Director, has been appointed as the new Chairman of the Board, effective April 30, 2026. The Board also approved the reconstitution of several key committees, including the Audit, Nomination and Remuneration, Stakeholders Relationship, Risk Management, and Corporate Social Responsibility Committees, effective from April 30, 2026.